Syndax Overview

  • Founded
  • 2005
Founded
  • Status
  • Public
  • Employees
  • 43
Employees
  • Stock Symbol
  • SNDX
Stock Symbol
  • Share Price
  • $14.89
  • (As of Thursday Closing)

Syndax General Information

Description

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Contact Information

Website
www.syndax.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 35 Gatehouse Drive
  • Building D, Floor 3
  • Waltham, MA 02451
  • United States
+1 (781) 000-0000

Syndax Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Syndax Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.89 $15.93 $13.02 - $25.68 $813M 54.6M 594K -$1.82

Syndax Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 696,914 899,773 167,058 20,921
Revenue 13,512 1,517 1,517 1,517
EBITDA (89,518) (71,553) (57,526) (75,825)
Net Income (91,695) (73,158) (56,047) (73,961)
Total Assets 239,503 300,613 63,525 83,938
Total Debt 21,645 20,536 897 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Syndax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Syndax‘s full profile, request access.

Request a free trial

Syndax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Syndax‘s full profile, request access.

Request a free trial

Syndax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination
Drug Discovery
Waltham, MA
43 As of 2020
00000
000000000 00000

00000000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occ
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

00 00000

lamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
0000 000000000
Copenhagen, Denmark
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Syndax Competitors (72)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00 0000000 Venture Capital-Backed Copenhagen, Denmark 00 00000 00000000 00000
0000000 0000000000 Corporation San Carlos, CA 000 00000 00000000 00000
0000000 000000 Formerly VC-backed Lyon, France 000 00000 00000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
You’re viewing 5 of 72 competitors. Get the full list »

Syndax Patents

Syndax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2021523359-A Patient selection for combination therapy Pending 07-May-2018 000000000000
CA-3099702-A1 Selection of patients for combination therapy Pending 07-May-2018 000000000000
AU-2019266231-A1 Selection of patients for combination therapy Pending 07-May-2018 000000000000
EP-3791185-A1 Selection of patients for combination therapy Pending 07-May-2018 000000000000
US-20210239697-A1 Selection of patients for combination therapy Pending 07-May-2018 G01N33/56966
To view Syndax’s complete patent history, request access »

Syndax Executive Team (21)

Name Title Board Seat Contact Info
Briggs Morrison MD Chief Executive Officer & Board Member
Richard Shea Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Michael Metzger Chief Operating Officer, Operations & Board Member
Peter Ordentlich Ph.D Chief Scientific Officer & Founder
Kathryn Corzo Director, Clinical Liaison & Medical Communications
You’re viewing 5 of 21 executive team members. Get the full list »

Syndax Board Members (21)

Name Representing Role Since
Arthur Pappas Pappas Capital Board Member 000 0000
Briggs Morrison MD Syndax Chief Executive Officer & Board Member 000 0000
Dennis Podlesak Self Chairman & Board Member 000 0000
Fabrice Egros Ph.D Syndax Chairman 000 0000
Jennifer Jarrett Self Board Member 000 0000
You’re viewing 5 of 21 board members. Get the full list »

Syndax Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Syndax Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Syndax‘s full profile, request access.

Request a free trial